Wednesday, February 16, 2011

Drug rights sales pushes InterMune to $206M Q4 profit

The sale of rights to the drug danoprevir in October helped push Brisbane’s InterMune Inc. to a $206.1 million profit in the December quarter.
InterMune (NASDAQ: ITMN) brought in $175 million in that sale, and that, combined with about $57.3 million leftover from payments for a terminated agreement by giant F. Hoffman-La Roche Ltd., added up to the unusual profit. A year ago in the December quarter, InterMune lost $28.6 million.

No comments:

Post a Comment